|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Global ATLAS Surveillance data 2014-2020 Inclusive** |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| ***Antibacterial susceptibility for 952 isolates positive for OXA-48\**** |  |  |  |  |  |  |  |  |  |  |  |
|  | Ceftazidime-Avibactam | Meropenem | Imipenem | Ciprofloxacin | Levofloxacin | Tigecycline | Ceftriaxone | Ceftazidime | Aztreonam | Colistin | Gentamicin  | Amikacin |
| **EUCAST MIC for *Enterobacterales*** | <=8 | <=2 | <=2 | <=0.25 | <=0.5 | <=0.5 | <=1 | <=1 | <=1 | <=2 | <=2 | <=8 |
| **Susceptible**  | 948 | 390 | 283 | 37 | 94 | 481 | 14 | 108 | 108 | 748 | 205 | 679 |
| **Number of isolates**  | 952 | 952 | 952 | 539 | 952 | 952 | 250 | 952 | 952 | 952 | 539 | 952 |
| **% Susceptible**  | ***99.6*** | ***41.0*** | ***29.7*** | ***6.9*** | ***9.9*** | ***50.5*** | ***5.6*** | ***11.3*** | ***11.3*** | ***78.6*** | ***38.0*** | ***71.3*** |
|  \*Those co-expressing metallo beta-lactamases [IMP/VIM/NDM] have been excluded |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| ***Individual susceptibility of the 4 isolates expressing OXA-48 that were not suscpetible to CAZ-AVI*** |  |  |  |  |  |  |  |  |  |
|  | Meropenem | Imipenem | Ciprofloxacin | Levofloxacin | Tigecycline | Ceftazidime | Aztreonam | Colistin | Gentamicin  | Amikacin |  |  |
| Number of suscpetible isolates | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 3 | 2 | 2 |  |  |
| Total number available for comparison | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |  |  |
|  |   |   |   |   |   |   |   |   |   |   |  |  |
| Isolate 1 |   |   |   |   |   |   |   |   |   |   |  |  |
| Isolate 2 |   |   |   |   |   |   |   |   |   |   |  |  |
| Isolate 3 |   |   |   |   |   |   |   |   |   |   |  |  |
| Isolate 4 |   |   |   |   |   |   |   |   |   |   |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Non-Susceptible |  |  |  |  |  |  |  |  |  |  |  |
|  | Susceptible  |  |  |  |  |  |  |  |  |  |  |  |